---
source_pdf: "../../PDFs/Pitch-Decks/Thyme Care Overview - Series B Fundraise.pdf"
type: pitch-deck
ingested: 2025-12-20
original_filename: Thyme Care Overview - Series B Fundraise.pdf
---

> **Original:** [[../../PDFs/Pitch-Decks/Thyme Care Overview - Series B Fundraise.pdf|View Original PDF]]

## Page 1

**Text:**
carlos@section32.com

Thyme Care

Investor Presentation
Q1'23

Thyme Care

**Images/Charts/Diagrams:**
[IMAGE: Photo showing two elderly people, an older man with white hair and beard in a knit sweater looking thoughtful, with an elderly woman with white hair wearing glasses visible behind him, in what appears to be a home setting]

## Page 2

**Text:**
carlos@section32.com
Thyme Care Leadership Team

Robin Shah
Co-Founder & CEO

Before launching Thyme Care, Robin ran a founding member of OncoSelect, where he served as the Chief Commercial Officer, focusing on provider development, marketing, strategy, and technology/analytics. Prior to OncoSelect, Robin was one of the first employees at Flatiron Health where he served as VP, President of Marketing and Strategy. Robin started his career in oncology managing a comprehensive cancer center in his hometown, Gettysburg, PA.

Bobby Green, MD
Co-Founder, President & CMO

Bobby Green is a medical oncologist. He received his MD at Duke and did his residency and fellowship at the University of Pennsylvania. Prior to launching Thyme Care, Bobby was the Chief Medical Officer at Flatiron Health. Before Flatiron, he was managing physician at Palm Beach Cancer Institute (which became part of Florida Cancer Specialists) from 1999-2014. Bobby currently serves on the board of the Community Oncology Alliance and continues to care for cancer patients part time.

Brad Diephuis, MD
Chief Business Officer

Brad Diephuis a primary care physician, clinically trained at Brigham and Women's Hospital and holds BA/MS and MBA degrees from Harvard. Before joining Thyme Care, Brad served as a Senior Advisor at the Center for Medicare and Medicaid Innovation (CMMI). Previously, Brad served as Co-Founder and CEO of Herald Health, and later held a leadership role at Persistent Systems. Brad maintains a small primary care practice part-time.

Julia Ivanova
SVP, Payer Partnerships

Julia was most recently the SVP of Business Development for US Value-Based Kidney Care business at U.S. Renal Care. Previously, she was VP of Business Development at Landmark Health where she was responsible for securing value-based agreements with payers and health systems to improve members' outcomes. Prior to Landmark, Julia was a Partner with Wynns Healthcare Strategy Consulting group where she specialized in value-based care strategy, government product strategy and care management program design.

Brian Dorsey, MD
Medical Director

Brian Dorsey is a complex care physician and Thyme Care's Medical Director. He has more than 9 years of experience improving care delivery to underserved populations and in clinical and leadership roles with at-risk populations at Montefiore Medical Center, Galileo Medical Center, and CityBlock Health.

Michelle Pierre-Poinsette
VP, Legal & Compliance

Michelle Pierre-Poinsette is Thyme Care's Vice President of Legal & Compliance. She is an experienced legal counsel with over 19 years working in healthcare advising health plans on strategies to improve health outcomes while ensuring compliance with applicable laws. Before joining Thyme Care, Michelle worked at Healthfirst, one of the nation's largest not-for-profit health plans.

**Images/Charts/Diagrams:**
[IMAGE: Six circular headshot photos of the leadership team members arranged in a row]

## Page 3

**Text:**
carlos@section32.com
Thyme Care Leadership Team

Nate Brown
VP, Clinical Operations

Alphan Kirayoglu
VP, Data Science

Rob Rodkey
VP, Engineering

Scott Voigt
VP, Product

Manya Ellenberg
VP, People

Ashley Patton
Head of Corporate Strategy

Brian Stockton
Head of Strategic Finance

Nikkayla Page
Head of Marketing Communications

Julia Stanton
Director of Member Experience

Alefiyah Shambhoora
Head of Strategic Initiatives

**Images/Charts/Diagrams:**
[IMAGE: Ten circular headshot photos of additional team members arranged in two rows]
[LOGOS: Multiple company logos displayed at bottom including Aledade, Carbon Health, CareBox, CityBlock, Flatiron, Florida Cancer Specialists & Research Institute, Galileo, Davita, healthfirst, (h|s|), Included Health, OneOncology, one medical, Zocdoc, Landmark, Penn Medicine]

## Page 4

**Text:**
carlos@section32.com
Our Board of Directors

Vineeta Agarwala, MD, PhD
General Partner,
Andreessen Horowitz

Brenton Fargnoli, MD
Managing Partner,
AlleyCorp

Bill Frist, MD OBSERVER
Co-Founder & Partner,
Frist Cressey Ventures

Vivek Garipalli
Co-Founder & CEO,
Clover Health

Bobby Green, MD
Co-Founder, President & CMO,
Thyme Care

Jay Rughani OBSERVER
Investment Partner,
Andreessen Horowitz

Robin Shah
Co-Founder & CEO,
Thyme Care

Puneet Singh
Former CEO, Quartet Health

Our Advisors and Clinical Team

Sam Mullangi, MD
Medical Director, Oncology

Manali Patel, MD, MPH, MS
Asst. Prof. of Medicine
Division of Oncology,
Stanford Medicine

Ravi Parikh, MD, MPH, FACP
Asst. Prof. of Medical Ethics and
Health Policy and Medicine,
University of Pennsylvania

Kush Sachdeva, MD
President & Managing
Partner, Southern Oncology-
Hematology & Oncology

Stephen Schleicher, MD, MBA
Chief Medical Officer &
Medical Oncologist,
Tennessee Oncology

Jeff Vacirca, MD, FACP
CEO, New York Cancer &
Blood Specialists

Bob Badal
Co-Founder & Chief Revenue
Officer, Strive Health

Jeff Patton, MD
Chief Executive Officer,
OneOncology

Alti Rahman
Practice Administrator,
Oncology Consultants

Our Investors

**Images/Charts/Diagrams:**
[IMAGE: Multiple circular headshot photos of board members, advisors, and clinical team arranged in rows]
[LOGOS: Andreessen Horowitz, Casdin Capital, Bessemer Venture Partners, AlleyCorp, Frist Cressey Ventures]

## Page 5

**Text:**
carlos@section32.com
TAM & Tailwinds

It's time to change the cancer care reimbursement model.

PCP Attribution
‚Ä¢ Affordable Care Act, ACA (2010)

Nephrology Specialist Attribution
‚Ä¢ Comprehensive ESRD Care Model (2015)
‚Ä¢ The 21st Century Cures Act (2016)
‚Ä¢ Kidney Care Choices, KCC (2022)

Oncology Specialist Attribution
‚Ä¢ Oncology Care Model, OCM (2016)
‚Ä¢ Enhancing Oncology Model, EOM (2023)

$350B
Population spend

$11K
Spend per patient per year

$162B
Population spend

$28K
Spend per patient per year

$200B
Population spend

~$90K
Spend per patient per year

**Images/Charts/Diagrams:**
[DIAGRAM: Arrow showing progression from PCP Attribution to Nephrology Specialist Attribution to Oncology Specialist Attribution]
[LOGOS: Multiple healthcare company logos under each category including VillageMD, Iora, Privia under PCP; Monogram Health, Strive Health under Nephrology; Somatus, Evergreen, Cricket Health, Interwell Health under Nephrology; and Thyme Care logo under Oncology]

## Page 6

**Text:**
carlos@section32.com
The Problem

Despite scientific advances, people living with cancer are under-supported.

Thyme Care

**Images/Charts/Diagrams:**
[IMAGE: Photo of an elderly woman in pink/coral clothing lying on a couch with a young child, appearing to be in a caring, intimate family moment]

## Page 7

**Text:**
carlos@section32.com
A Better Cancer Journey for All

Time to Care
Lisa's PCP refers her to an oncologist, but there is no availability for 4 weeks. Once she is diagnosed, she still can't start treatment for 3 more weeks.

No Social Support
When Lisa's car breaks down a few weeks later, she begins missing appointments when she can't get a ride ‚Äî causing gaps in the course of her care.

Acute Care Utilization
When Lisa experiences severe nausea one evening, her provider's office is closed, so she goes to the Emergency Department for care and is admitted to the hospital.

Financial Toxicity
The high OOP pharmacy expenses for Lisa's medications, as well as transport and ED visit costs, start to create serious financial strain and stress for Lisa.

Misaligned End of Life Care
Lisa had received an end of life preferences form before her first oncologist visit. The form was scanned into the chart, but no one reviewed her choices with her.

with standard care

with Thyme Care

Lisa is a 70 year old woman whose PCP has identified a suspected malignancy.

Rapid Access
Through Thyme Care's Rapid Access program, Lisa is scheduled with a high-quality oncology practice within two business days. They confirm her diagnosis, expedite workup and staging, and start treatment a week later.

Addressed Social Barriers to Care
When Lisa's car breaks down a few weeks later, her Thyme Care care partner connects her to a free local rideshare org to ensure she can attend her appointments.

Thyme Care Navigation
Lisa reports severe nausea in her daily Thyme Care symptom survey. Within an hour, a nurse calls to discuss her symptoms, and she is scheduled for a next-day visit for IV hydration and antiemetics. The nurse works with her oncologist to broaden her medication regimen as a preventative measure.

Drug Benefit Optimization
During Lisa's second round of chemo, Thyme Care identifies an opportunity to decrease Lisa's OOP pharmacy expenses, and coordinates with her provider to make the necessary changes.

Palliative and Hospice Care
Given her incurable cancer, Lisa's Thyme Care team encouraged a goals of care discussion with her physician. Palliative care was initiated soon afterwards and ultimately led to an appropriate transition to hospice earlier than otherwise.

Thyme Care

**Images/Charts/Diagrams:**
[IMAGE: Circular photo of an elderly Asian woman with grey hair and glasses]
[DIAGRAM: Timeline showing two parallel paths - "with standard care" and "with Thyme Care" - with icons representing different stages of care]

## Page 8

**Text:**
carlos@section32.com
Managed Population Opportunity

The complexity of caring for cancer patients drives excess spend and artificially low premiums.

$90K

$8,300 PMPY Addressable Spend

$1,000 End of Life Care

$2,300 Drug Costs

$60K

$4,000 Inpatient Care

$82,300 PMPY
Core Oncology Care

$1,000 ED Visits

$30K

$2,200 PMPY Premium Opportunity

~$17,000 PMPY
Existing Avg. Premiums

$0

Thyme Care

**Images/Charts/Diagrams:**
[CHART: Stacked bar chart showing breakdown of cancer care costs, with large purple section for Core Oncology Care ($82,300 PMPY) and smaller sections for addressable spend items, compared to a separate teal bar showing existing average premiums]

## Page 9

**Text:**
carlos@section32.com
Who We Are

Thyme Care is an oncology focused population management company, partnering with payers and risk-based entities to deliver better outcomes and lower costs through patient-centered navigation.

Virtual Care Team
Dedicated team of specialty nurses and care partners that assist members through their cancer journey.

Curated Provider Network
Relationships with community oncology and primary care practices to support high value interventions and drive a more coordinated experience.

Robust Technology + Analytics Platform
Intelligent care delivery platform that enables data-driven care guidance at scale, informed by advanced analytics, to drive decision-making and patient engagement.

Thyme Care

**Images/Charts/Diagrams:**
[IMAGE: Central circular photo of a middle-aged woman with shoulder-length blonde hair]
[DIAGRAM: Three circular icons around the central image representing Virtual Care Team (hands icon), Curated Provider Network (people icon), and the Technology Platform (at bottom)]

## Page 10

**Text:**
carlos@section32.com
Virtual Care Team

A passionate, oncology-trained team built to assist members through their journey.

Medical Director
Guides the care team in delivering the highest quality care via regular trainings and clinical oversight.

Complex Care Nurse
Clinically assesses high risk members, coordinating clinical and specialty care for members with complex chronic comorbid conditions.

Nurse Practitioner
Provides urgent clinical needs support, manages medication refills, and executes action plans created by the practice.

Thyme Care Nurse
Oversees ongoing clinical support, medication and diagnoses education, symptom monitoring, and outcomes improvement via adherence to treatments.

Care Partner
Advocates for a member's whole-person needs through their journey, addressing barriers to care, including financial and transportation assistance.

Thyme Care

**Images/Charts/Diagrams:**
[IMAGE: Central circular photo of a smiling Black woman]
[DIAGRAM: Five circular icons arranged around the central image, each representing different team roles with dotted lines connecting them to the center]

## Page 11

**Text:**
carlos@section32.com
Robust Technology + Analytics Platform

Proprietary technology guides care navigation and enables easy, real-time communication with providers for wraparound support.

Thyme Box is our oncology-tailored care management platform that guides our care team through evidence-based interventions.

EHR integration and our Google Chrome extension enable real time communication with providers to surface key notifications and updates.

üìã Playbook: Concerning Symptom - Diarrhea ‚úï

1/3 Tasks                                                33%

üîç Investigate concerning symptom
2/3 Subtasks                                            ‚åÑ

üîî Notify provider of the patient's concerning symptom
Due: 03/15/2023 ‚è∞ Est: 5 min üë§ Elizabeth Smith, RN

‚úì Outreach to patient about concerning symptom
Due: 03/15/2023 ‚è∞ Est: 15 min üë§ Elizabeth Smith, RN

‚úì Chart review: Identify any existing action plan to address diarrhea
Due: 03/15/2023 ‚è∞ Est: 10 min üë§ Elizabeth Smith, RN

üîΩ Educate patient about first line approaches to diarrhea management
0/2 Subtasks

‚Üê ‚Üí üîÑ üîí https://www.ehr.com/patient/first_last

EPIC

Notifications from Thyme Box

Name                    ‚Ä¢ Concerning Symptom: Diarrhea
                         45yo F with Breast Cancer c/o 
                         worsening diarrhea. 8 stools/day
                         without red flag symptoms.
                         No antidiarrheal meds at home.
                         Please prescribe Imodium following
                         standard protocol.

                         from Elizabeth Smith, RN
                         Tuesday, March 15, 2023 4:06pm

**Images/Charts/Diagrams:**
[SCREENSHOT: Two interface panels showing the Thyme Box care management platform and EHR notification system]

## Page 12

**Text:**
carlos@section32.com
Curated Provider Network

In-network oncology partnerships to drive a better patient experience and better outcomes.

Integrated Care Navigation
Thyme Care is embedded in the practice's EMR and workflow in order to support care navigation, triage, and site of service in markets where payer partnerships are established.

"Thyme Care is keeping everyone at the practice informed of what is going on and has helped bridge the gap when patients might be lost to follow up. Our patients really appreciate that this program is in place."

Executive Director
Thyme Care Oncology Group

Tech & Incentives
Enable physicians in our network to drive value through our tech platform and incentive based arrangements.

**Images/Charts/Diagrams:**
[LOGOS: OneOncology (with ribbon logo), AON, RCCA, New York Cancer & Blood Specialists (with ribbon logo)]

## Page 13

**Text:**
carlos@section32.com
Our Outcomes

Real documented outcomes showing proven results.

Market Leading Member Enrollment
70%+
Month-over-month conversion rate
with Medicare Advantage client

30%+
<3 month new client onboarding enrollment rate
with Commercial client

Deep Member Satisfaction
9.7/10
Member satisfaction rate

>99%
Month-over-month retention

Proven Results
$429 PEMPM*
Savings from core navigation intervention

Study presented at ASCO Quality Symposium 2022

Thyme Care
*This study was published on our intervention which was focused on high/medium acuity populations. Measured on a per engaged member per month basis.

**Images/Charts/Diagrams:**
[CHART: Statistics displayed in large text format showing enrollment rates, satisfaction scores, and cost savings]

## Page 14

**Text:**
carlos@section32.com
Enrollment

Outcomes fueled by market-leading* enrollment.
Enrollment is driven by enrollment specialists, provider integration, and thoughtful algorithms to reach members.

AHNJ Enrollment
>30% in our first 3mo across the entire population, significantly outperforming industry standards.*

‚ñ† Enrolled Count ‚ñ† Program Population Count ‚Äî Enrollment Rate

0.4                                                          1000

0.3                                                          750

0.2                                                          500

0.1                                                          250

0.0    1/2/23  1/9/23  1/16/23  1/23/23  1/30/23  2/6/23  2/13/23  2/20/23  2/27/23  3/6/23  3/13/23  3/20/23    0

Clover Conversion
Drove 70%+ month > month conversion on high/medium acuity population.

600

400

200

0    7/2021  8/2021  9/2021  10/2021  11/2021  12/2021  1/2022  2/2022  3/2022  4/2022  5/2022  6/2022  7/2022  8/2022  9/2022  10/2022  11/2022  12/2022  1/2023

Thyme Care
*Landmark: 20-30% at 12 months; Livongo - 35% at 9 months.

**Images/Charts/Diagrams:**
[CHART: Two charts showing enrollment data - left chart shows AHNJ enrollment over time with bars and line graph, right chart shows Clover conversion data as a bar chart over monthly periods]

## Page 15

**Text:**
carlos@section32.com
Savings Expansion

Thyme Care engages members through targeted, high-value interventions to deliver higher-value care and a better experience.

Value Opportunities ‚óè Commercial ‚óè MA ‚óè EOM

Core Navigation Services ‚óè‚óè‚óè
Intervention: Structured symptom management interventions tailored to the member's cancer journey and coordination for palliative care and end-of-life options.

Value: ED and hospitalization reduction and avoidance of inappropriate end of life care.

Site of Service ‚óè
Intervention: Integration with providers (PCPs and oncologists) ensures actively treating members receive care at the most appropriate facility.

Value: Reduced TCOC by providing therapy and imaging in the community.

Drug Benefit Optimization ‚óè
Intervention: Analytics and deep HVAN relationships ensure that costly specialty therapeutics are billed to the optimal benefit.

Value: Identical infusion therapies billed under Part D instead of Part B trigger decreased financial toxicity to patient and savings in the form of CMS reinsurance.

Enhanced Diagnosis Capture ‚óè‚óè
Intervention: Robust analytics and member engagement address incomplete diagnosis documentation in order to build a more informed view of a members cancer.

Value: Informed care plans, improved member experience and increased premium.

Thyme Care

**Images/Charts/Diagrams:**
[DIAGRAM: Four boxes showing different value opportunities with color-coded dots indicating which programs (Commercial, MA, EOM) each applies to]

## Page 16

**Text:**
carlos@section32.com
What We Do

We are expanding our provider relationships to grow our impact and serve as a competitive moat.

Support Practices in CMMI's Enhancing Oncology Model (EOM)
With our existing technology and navigation, we are able to capture a new market by supporting oncology practices who decide to participate in CMMI's EOM.

What this unlocks:
‚Ä¢ Additional lives under management.
‚Ä¢ Wedge to gain provider trust and embed deeper with their teams.

Deeper Partnerships with Providers
With proven results, we will launch partnerships through joint venture (depending on the market) to enroll oncology practice members into risk-based agreements for their members with plans.

What this unlocks:
‚Ä¢ Competitive moat through deep partnerships.
‚Ä¢ Enhanced savings through provider alignment.
‚Ä¢ Expansion of contracted lives.

**Images/Charts/Diagrams:**
[DIAGRAM: Two purple sections showing the two main expansion strategies]

## Page 17

**Text:**
carlos@section32.com
Financials

Thyme Care's Economic Model: Near-Term Projections

Per Member per Year Economic Model

Contract Model

$10,500

$10,000
$2,200 Premiums

‚Ä¢ Thyme Care enters risk-based contracts with payers and other risk-bearing entities.

‚Ä¢ We charge an advanced payment for operating capital and receive additional shared savings based on performance against a benchmark.

$7,500

‚Ä¢ We target capturing 50% of the economic value generated in the partnership. This is reflected within "Thyme Care Share", which is inclusive of advanced payment and shared savings.

$5,000

$8,300 MedEx
$4,800
$2,500
$1,040
$2,400
$1,360

‚Ä¢ Maintain low operating costs, fueled by custom-built tech.

$0
Total Addressable    Value Driven by     Thyme Care        Thyme Care        Thyme Care
Opportunity          Thyme Care         Share             Direct Costs      Gross Profit

Thyme Care    Note: This is modeled for Medicare Advantage. Projections for other lines of business vary slightly and can be made available by request.

**Images/Charts/Diagrams:**
[CHART: Waterfall chart showing economic model breakdown from Total Addressable Opportunity ($10,500) down to Thyme Care Gross Profit ($1,360)]

## Page 18

**Text:**
carlos@section32.com
Financials

Thyme Care's Economic Model: Long-Term Projections

Per Member per Year Economic Model

How we get there

$10,500
Long term projections (in 2023 dollars)

$10,000
$2,200 Premiums     2023 / 2024 Management Expectations

‚Ä¢ Deepened relationships with Thyme Care High-Value Aligned network will drive these economics through care model integration and incentive models.

$7,500
$6,700

‚Ä¢ Continued refinement of our existing interventions.

$1,900

‚Ä¢ Launch of new interventions around high value clinical decisions.

$5,000
$8,300 MedEx
$3,350
$950         $2,310
$2,500       $4,800
1040         $950
$2,400
$1,360

$0
Total Addressable    Value Driven by     Thyme Care        Thyme Care        Thyme Care
Opportunity          Thyme Care         Share             Direct Costs      Gross Profit

Thyme Care    Note: This is modeled for Medicare Advantage. Projections for other lines of business vary slightly and can be made available by request.

**Images/Charts/Diagrams:**
[CHART: Enhanced waterfall chart showing long-term projections with higher values, including $6,700 for Value Driven by Thyme Care and $2,310 for Thyme Care Gross Profit]

## Page 19

**Text:**
carlos@section32.com
Illustrative Margin Expansion

Revenue & GM grow as we achieve more of the addressable spend.

Per Member per Year Economic Model

Margin Details

$4,000
                                                           69% GM
                                                           $3,350

‚Ä¢ Direct costs are covered through upfront fees alone.

$3,000
                                                           
                                              57% GM        ‚Ä¢ Shared savings provide high GM % upside based on current projections.
                                              $2,400
$2,000                                                     ‚Ä¢ Room for additional margin growth through cost of care efficiencies and increased value driven.

                           21% GM
                           $1,320                          ‚Ä¢ Direct costs are inclusive of provider incentives.
$1,000      $1,040

$0
Direct Costs    Advanced Payment (AP)    AP + Shared Savings     AP + Shared Savings
                                        2023 / 2024 Management   Long Term Projections
                                        Expectations

Thyme Care

**Images/Charts/Diagrams:**
[CHART: Bar chart showing margin expansion across four stages, from Direct Costs ($1,040) to Long Term Projections ($3,350), with GM percentages labeled]

## Page 20

**Text:**
carlos@section32.com
Growth Forecast

Strong near term growth against a massive TAM opportunity.

Projected Contracted At-Risk Lives

$35,000
                                        30,344
                            4,713
                                        $329
                            5,070
                                        $1,328
                            8,915
$17,500        14,406      
                3,906       11,646      $1,750    $1.5 B
                                        $450
                3,500       
900             3,079                   $1,113
                3,921       $0.1 B      $215
$0                                      $435
2022           2023        2024        $355
                                        $0
                                        2022    2023    2024

Medicare Advantage        Commercial             Enhancing Oncology Model    At-Risk Providers
$57B    628k            $111B   784k            $29B    250k                $16B    85k
MSUM    Cancer Lives    MSUM    Cancer Lives    MSUM    Cancer Lives        MSUM    Cancer Lives

Projected Contracted MSUM (Medical Spend Under Management)
$3,500
                                        $3.3 B
                                        $573

**Images/Charts/Diagrams:**
[CHART: Two stacked area charts showing growth projections for contracted lives and medical spend under management from 2022-2024, with color-coded segments for different business lines]
[BOXES: Four colored boxes at bottom showing TAM data for each business segment]

## Page 21

**Text:**
carlos@section32.com
Pipeline

Robust pipeline to support projected growth.¬π

As of March 25th, 2023

Stage        Introduction    Sales Pitch¬≤    Opportunity Analysis¬≥    Proposal    Contracting    Closed Won    Total

Commercial   6              7               1                        1           2                            18
                                                                                                   AmeriHealth  39% national
                                                                                                   NEW JERSEY

Medicare     8              8               1                        2           1‚Å¥                           20
Advantage                                                                                         Clover      30% national
                                                                                                   Health

At-risk PCP  2              2               1                        1                                        7

Active Cancer 16.0k          17.0k           5.8k                    1.8k        3.6k           1.5k         44.7k
Lives

Oncology     $1.7b          $1.8b           $488.8m                 $179.9m     $356.7m        $127.1m      $4.6b
MSUM

1. Lines of Businesses and local markets for national plans are treated as individual deals.

2. This stage typically requires several meetings and is an important part of positioning TC's value to the client. During this stage, we share a market-data driven financial model that illustrates our outside-in understanding of how our interventions could impact the client.

3. During the Opportunity Analysis phase, Thyme leverages the client's claims data to create a financial model that illustrates how our interventions could impact the client. This model is an important input for Thyme when we start to discuss financial structures with clients.

4. This represents a renewal and expansion of our existing contract with Clover Health.

**Images/Charts/Diagrams:**
[TABLE: Pipeline data showing different stages of deals across business segments, with counts and dollar amounts for each stage and segment]

## Page 22

**Text:**
carlos@section32.com
Fundraise Goals

Thyme Care has the team, model, and results to scale value-based care in oncology.

Expand to support more cancer patients

Invest in quicker path to shared savings growth

Expand partnerships with providers

Build upon first mover advantage

Thyme Care

**Images/Charts/Diagrams:**
[ICONS: Four purple icons on the right side representing each goal - hands/heart for patient support, plant/growth for savings, building for provider partnerships, and rocket for first mover advantage]

## Page 23

**Text:**
carlos@section32.com

Thyme Care

Thank you!                Cancer care, reimagined.

                         Extending the reach of high-quality cancer care by creating
                         a better experience, improved outcomes, and lower costs.

Thyme Care Medical, PLLC, ('Thyme Care Provider') is a health care provider offering clinical cancer support services to its patients. Thyme Care Provider does not direct diagnosis or prescribing of medication for cancer treatment. Thyme Care, Inc. provides management support services to Thyme Care Provider or cancer support services to its members.

**Images/Charts/Diagrams:**
[DESIGN: Purple gradient background with large text layout]

## Page 24

**Text:**
carlos@section32.com
Provider Pipeline

Thyme's Oncology Provider Pipeline

As of April 2, 2023

[THIS IS TABLE: Provider pipeline data with columns for SKU, Identification, Establish Contact, Establish Value, Agreement Pending, Closed Won, and Total]

High-Value Aligned Network | 8 | 2 | 2 | 3 | 5 | 20

Tech + Incentives | 8 | 7 | 6 | 0 | 0 | 21

Enhanced Oncology Model | 11 | 5 | 6 | 1 | 1 | 24

JV Partnership with Providers | 0 | 0 | 0 | 0 | 0 | 0

Est. # of EOM Lives¬≤ | 21.0k | 3.1k | 5.6k | 990 | 1.9k | 31.7k

# of Providers | 1.6k | 689 | 1.8k | 180 | 440 | 4.8k

1. SKUs, MSO partners are treated as individual deals.
2. Assumes 18 members per provider.
3. This deal represents 108 oncologists.

**Images/Charts/Diagrams:**
[TABLE: Detailed pipeline breakdown showing different provider partnership types and their progression through various stages]
